Loading...
01/10 22:42
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows strong financial performance with significant revenue growth, high gross margins, and positive free cash flow. The Q&A highlights opportunities with major companies like AMD and Altera, and the focus on AI and data centers is promising. The management's avoidance of booking details is a minor concern, but overall, the optimistic guidance, strong partnerships, and strategic investments suggest a positive outlook for the stock price.
Annual Contract Value plus Royalties $74.9 million, a 24% year-over-year growth. This growth was driven by increased product adoption in chiplets and SoCs across multiple vertical markets, particularly in AI applications, which accounted for over half of the licensing dollars.
Total Revenue $17.4 million, an 18% year-over-year increase. This growth was attributed to strong deal execution and increased adoption of Arteris technology.
Trailing 12-Month Variable Royalties 36% higher year-over-year. This increase reflects the growing adoption of Arteris' products and solutions.
Remaining Performance Obligations $104.7 million, a 34% year-over-year increase. This milestone was achieved due to strong deal execution and increased customer commitments.
Non-GAAP Gross Profit $15.9 million, representing a gross margin of 91%. This reflects efficient cost management and strong revenue growth.
GAAP Gross Profit $15.6 million, representing a gross margin of 90%. This is consistent with the company's operational efficiency.
Non-GAAP Operating Expense $19.5 million. The company reinvested in technology innovations, solution support, and its global sales team, while achieving a 15% improvement in operating expense as a percentage of revenue year-to-date compared to 2023.
GAAP Operating Expense $24.4 million. This reflects ongoing investments in growth and innovation.
Non-GAAP Operating Loss $3.5 million, in line with guidance. This was due to controlled G&A spending and reinvestment in growth areas.
GAAP Operating Loss $8.7 million, compared to a loss of $7.9 million in the prior year period. This reflects increased investments in growth initiatives.
Non-GAAP Net Loss $3.8 million or $0.09 per share. This was in line with expectations and reflects the company's strategic investments.
GAAP Net Loss $9 million or $0.21 per share. This was higher than the prior year due to increased operating expenses.
Cash, Cash Equivalents, and Investments $56.2 million, with no financial debt. This indicates a strong liquidity position.
Free Cash Flow Positive $2.5 million. This was above the midpoint of guidance and reflects efficient cash management.
FlexGen Smart NoC IP: Broad applicability in chiplets and SoCs, with adoption by companies like Altera, AMD, and NanoXplore for various applications including automotive, aerospace, and industrial sectors.
Ncore and FlexNoC interconnect IPs: Used in IO Hub chiplets for multi-die SoC architectures, addressing high bandwidth, low latency, and energy efficiency needs.
Magillem registers integration automation software: Recognized for innovation and announced earlier this year.
AI applications: Accounted for over half of licensing dollars in Q3, reflecting growing adoption of Arteris system IP technology from data centers to smart edge.
Automotive sector: FlexGen deployed by Dream Chip and a leading automotive OEM for next-generation EVs.
Industrial sector: NanoXplore licensed FlexGen for mission-critical computing in space and industrial applications.
Annual contract value plus royalties: Achieved a record $74.9 million, a 24% year-over-year growth.
Revenue: Total revenue for Q3 was $17.4 million, up 18% year-over-year.
Remaining performance obligations: Reached $104.7 million, a 34% year-over-year increase.
Collaboration with Alibaba Damo Academy: Aimed at optimizing performance between RISC-V CPU cores and Arteris data movement system IPs for AI server and automotive chips.
Joining Ultra Accelerator Link Consortium: Focus on establishing an optimized ecosystem for AI accelerators, collaborating with companies like AMD, AWS, and Microsoft.
Market Conditions: The semiconductor industry is accelerating efforts to increase performance and efficiency, especially driven by AI workloads and data centers. This creates a dependency on advanced foundry nodes (5-nanometer, 3-nanometer, 2-nanometer) and the Angstrom era of silicon, which could pose challenges in scaling and meeting demand.
Competitive Pressures: Arteris faces competition from other companies in the Ultra Accelerator Link Consortium, such as AMD, AWS, Cisco, Google, Intel, and Microsoft, which could impact its market share and growth.
Regulatory Hurdles: No explicit regulatory hurdles were mentioned in the transcript.
Supply Chain Disruptions: No explicit supply chain disruptions were mentioned in the transcript.
Economic Uncertainties: No explicit economic uncertainties were mentioned in the transcript.
Strategic Execution Risks: Arteris is heavily investing in technology innovations and global sales teams, which could strain financial resources if the expected top-line growth does not materialize. Additionally, the company is relying on ecosystem collaborations and customer adoption to drive growth, which may not meet expectations.
Fourth Quarter 2025 Guidance: ACV plus royalties expected to be between $74 million and $78 million. Revenue projected to range from $18.4 million to $18.8 million. Non-GAAP operating loss anticipated to be between $2.3 million and $3.3 million. Non-GAAP free cash flow expected to range from $0.2 million to $3.2 million.
Full Year 2025 Guidance: ACV plus royalties projected to exit 2025 at $74 million to $78 million, reflecting a $1 million increase from prior guidance. Revenue expected to be between $68.8 million and $69.2 million, also a $1 million increase from prior guidance. Non-GAAP operating loss forecasted to be between $12.5 million and $13.5 million. Non-GAAP free cash flow anticipated to range from $2.5 million to $5.5 million.
Market Trends and Strategic Focus: Arteris anticipates scaling demand driven by increasing design complexity and the transition to advanced foundry nodes (5-nanometer, 3-nanometer, 2-nanometer, and Angstrom era silicon). The company expects a growing shift from monolithic chips to chiplets for multi-die SoC architectures, particularly for AI infrastructure and data center applications. Accelerating demand for advanced chiplets and chips is expected due to the AI surge and the need for specialized computing.
Customer and Ecosystem Collaboration: Arteris foresees enhanced collaboration with major customers and ecosystem partners, such as Alibaba Damo Academy, to optimize performance and integration for AI server communications and automotive chips. The company expects these collaborations to accelerate innovation and adoption of its technologies.
The selected topic was not discussed during the call.
The earnings call summary shows strong financial performance with significant revenue growth, high gross margins, and positive free cash flow. The Q&A highlights opportunities with major companies like AMD and Altera, and the focus on AI and data centers is promising. The management's avoidance of booking details is a minor concern, but overall, the optimistic guidance, strong partnerships, and strategic investments suggest a positive outlook for the stock price.
The earnings call reveals strong financial performance with a 13% increase in revenue and a 15% rise in ACV plus royalties, reflecting growing demand. Record high revenue and strategic wins with major clients like AMD are positive indicators. While there are some concerns about expenses, the optimistic guidance for revenue and cash flow, alongside strategic partnerships and product developments, suggests a positive outlook. However, the lack of clarity on certain metrics in the Q&A slightly tempers enthusiasm, but the overall sentiment remains positive, likely leading to a stock price increase of 2% to 8%.
The earnings call presents mixed signals: record high revenue and strong ACV growth are positive, but operational losses and increased expenses due to currency fluctuations are concerning. Management's optimistic guidance is tempered by geopolitical risks and trade uncertainties. The Q&A reveals steady licensing activity and potential growth in FlexGen, but no acceleration in decision timelines. The lack of guidance on book-to-bill ratio is a red flag. Given these factors, a neutral stock price movement is likely, as positives are balanced by risks and uncertainties.
The earnings call shows strong financial performance with record high revenues and significant annual contract value plus royalties. Despite operational losses, improvements were noted, and guidance remains optimistic. The Q&A section highlighted strong product adoption and positive ASP trends. However, management's lack of clarity on specific bookings figures slightly tempers enthusiasm. Overall, the positive financial metrics and guidance suggest a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
